Gout

The group receiving Qingpeng ointment showed significant differences compared to the control group in VAS scores, joint mobility, and disappearance rate after treatment for acute gouty arthritis.

Electroacupuncture demonstrates superior analgesic effects and the ability to lower serum uric acid in patients with acute gouty arthritis when compared to conventional medication options.

Higher serum urate levels at baseline were linked to higher rates of recurrent gout.

Proactive disease management could result in more positive emotional and mental experiences in patients with gout.

After adjusting for confounders, data revealed higher levels of obesity indices were linked with a gradual and dose-dependent increase in urate levels.

Findings revealed an elevation of educational attainment by one standard deviation exhibited a protective effect against gout.

A review of 15 RCTS suggests that both electroacupuncture and conventional drugs demonstrate similar effectiveness in addressing pain for patients with acute gouty arthritis.

Gout incidence rate significantly increased after relieving urinary tract obstruction.

Mortality risks in gout have not improved in the United States in the past 3 decades, with a similar risk found among contemporary cases of gout in the United Kingdom.

There were no differences in patient-rated pain scores, time to flare resolution, and the risk of recurrent flare in patients initiating urate-lowering therapy during treatment and those delaying treatment.

Benign prostatic hyperplasia was 1.13-fold higher in those with gout when compared with controls.

Patients with gout had a 1.26-fold higher likelihood of experiencing migraines when compared with those without gout.

A study compared the efficacy of febuxostat and benzbromarone in treating gout, emphasizing the lack of consensus in previous research and the need for future, well-designed studies.

Compared to routine care, TCMD could better reduce the incidence of adverse events and the level of laboratory indicators.

Significant differences in the practice of primary healthcare physicians were observed based on medical specialty when treating and managing asymptomatic hyperuricemia and gout.

In this discussion, experts focus on emerging treatment options for gout and share tips for monitoring and managing gout in patients with comorbid conditions.

Various factors related to demographics, psychosocial behavior variables, and clinical characteristics were linked to health-related quality of life in patients with gout.

In this discussion, experts focus on emerging treatment options for gout and share tips for monitoring and managing gout in patients with comorbid conditions.

Findings provide a theoretical framework for the early diagnosis and treatment of heart disease in patients with gout, especially for older individuals and those with hypertension.

Patients with gout who did not experience recurrent flares had a shorter mean time between diagnosis and the start of urate-lowering therapy compared with those who had ≥1 flare.

Patients with gout achieving target serum uric acid levels showed good adherence to urate-lowering therapy, used antihypertensive agents, and lacked a family history of gout.

This analysis resulted in several valuable insights related to the landscape of gout patients’ changes in their blood immune cells between flares and periods of remission.

Waist circumference and high lipid levels were associated with poor disease outcomes in gout, including flares and failure to achieve treatment target.

This new data expanded upon research into gout’s molecular pathogenesis and into ULT for managing non-gout diseases such as hyperuricemia.

Patients with the highest Dietary Inflammatory Index have an increased risk of gout.